Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab in Resectable Hepatocellular Carcinoma
NCT06954116Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Started Aug 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06954116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954116.